**Core tip:** Bile acid diarrhea develops when excessive amounts of bile acids enter the terminal ileum and exceed the intestinal absorptive capacity. The excess bile acids enter the colon and cause secretory diarrhea. We report a patient with multiple potential causes of chronic diarrhea and suggest a systematic strategy for the diagnosis and treatment of this condition. Furthermore, we describe the use of a new treatment for severe bile acid diarrhea, obeticholic acid, which stimulates the farnesoid X receptor of the terminal ileum and increases fibroblast growth factor 19, thereby decreasing hepatic bile acid production *via* negative feedback.

INTRODUCTION
============

Chronic secretory diarrhea causes intestinal losses of water, sodium, and potassium\[[@B1]\]. In severe cases, it may negatively affect the fluid and electrolyte balance. Chronic secretory diarrhea may be caused by intestinal inflammation, infection, drug side effects or abuse, neuroendocrine tumors, functional diarrhea, or bile acid diarrhea (BAD). When no cause is identified, the condition is termed diarrhea-predominant irritable bowel syndrome (IBS-D)\[[@B2]\].

BAD occurs when excess amounts of bile acids enter the colon and induce colonic fluid and electrolyte secretion and motility changes\[[@B3]\]. Based on the pathophysiology, BAD is classified as type 1, which is caused by ileal resection, disease, or injury, type 2, which consists of primary or idiopathic BAD, and type 3, which is secondary to other conditions, *e.g*., cholecystectomy\[[@B4]-[@B6]\].

The medical treatments of BAD include the bile acid sequestrants colestyramine and colesevelam\[[@B3],[@B7],[@B8]\]. Antisecretory or antimotility drugs such as loperamide and proton pump inhibitors may be added. Some patients with BAD experience an insufficient effect of the available conventional medical treatments and suffer from an impaired quality of life\[[@B9],[@B10]\].

BAD is proposed to result from defective gut-liver feedback mechanisms. Hepatic bile acid synthesis is inhibited by fibroblast growth factor 19 (FGF19) that is produced by ileal enterocytes upon stimulation by bile acids in the terminal ileum *via* the farnesoid X receptor (FXR)\[[@B5],[@B11]\]. Decreased circulating FGF19 levels have been reported in patients with primary BAD\[[@B12]\] and in patients with Crohn's disease and diarrhea\[[@B13]\]. Obeticholic acid, a potent FXR agonist, stimulates ileal FGF19 production and may thereby decrease hepatic bile acid production in BAD\[[@B14]\]. Obeticholic acid is currently used to treat primary biliary cholangitis\[[@B15],[@B16]\] and non-alcoholic steatohepatitis\[[@B17],[@B18]\], but it may also improve BAD\[[@B14]\].

In this case report, we describe the investigations and treatments of a 32-year-old woman with Crohn's disease who suffered from chronic secretory diarrhea that could be potentially attributed to multiple causal factors. Because no infectious, inflammatory, or metabolic cause was demonstrated other than severe bile acid malabsorption, both type 1 and type 2 BAD were considered. The patient experienced a marked and sustained improvement following treatment with obeticholic acid.

CASE REPORT
===========

A 32-year-old Caucasian woman was referred to our unit for refractory diarrhea lasting 10 years. She had a 15-year history of recurrent depression and primary tonic-myoclonic epilepsy. Following the onset of diarrhea, she had been diagnosed with colonic Crohn's disease, and ^75^selenium homotaurocholic acid test (SeHCAT) scintigraphy\[[@B19]\] performed six years before referral to our unit had revealed a day-7 relative bile acid retention of 0, indicating severe bile acid malabsorption. Conventional treatments for BAD with the bile acid sequestrants colestyramine and colesevelam had a limited or transient effect, and the diarrhea had been unresponsive to antisecretory treatments such as loperamide and codeine phosphate. At the time of referral, the patient received low-dose 6-mercaptopurine for Crohn's disease, 625 mg colesevelam three times per day, 2-8 mg of loperamide per day for BAD, 1500 mg of levetiracetam per day for depression, and 400 mg of lamotrigine per day for epilepsy. The doses of both levetiracetam and lamotrigine had been optimized using therapeutic drug monitoring. Prior treatments also included 40 mg of escitalopram per day and 225 mg of venlafaxin per day, which led to poor control of the depression and did not affect bowel function. Anti-inflammatory Crohn's disease treatments with infliximab, adalimumab, natalizumab, and vedolizumab had been provided before referral and did not affect the diarrhea. Crohn's disease remission had been verified *via* a colonoscopy and fecal calprotectin measurement. The duodenal biopsies were normal. The patient had not undergone bowel surgery.

During the first admission to our unit, the results from all investigations were reviewed, and a diagnostic workup was planned (Table [1](#T1){ref-type="table"}). The patient's height and weight were 52 kg and 170 cm, respectively. Biochemical analysis revealed severe electrolyte deficiency with low plasma levels of potassium and magnesium. Although the plasma sodium level was normal, sodium depletion was indicated by the urinary sodium being below the detection limit using both single urine measurements and an analysis of a 24-h urine collection. Fecal cultures were negative for *Campylobacter*, *Salmonella*, *Yersinia*, and *Shigella* species, but a PCR toxin test for *Clostridium difficile* was positive. A 10-d trial of 125 mg of vancomycin four times per day had a transient effect on the diarrhea, and repeat fecal tests were negative. MRI of the small bowel and pan-enteric double balloon endoscopy revealed endoscopic remission, and duodenal, jejunal, ileal, and colonic biopsies were normal. A laxative screen and markers of systemic infection or metabolic disease were normal (Table [1](#T1){ref-type="table"}). All medical treatments were reviewed, and because the diarrhea persisted despite conventional treatment, trials of spironolactone, octreotide, and liraglutide were initiated during the admission but were without effect or produced unacceptable side effects (Table [2](#T2){ref-type="table"}). The dose of 6-mercaptopurine was optimized using thiopurine metabolite measurements, revealing a normal TPMT genotype and phenotype, an E-TGN level of 247 nmol/mmol HGB, and an E-MeMP level of 2354 nmol/mmol HGB.

###### 

Potential causes of chronic diarrhea and their diagnostic investigations and results in a patient with severe bile acid diarrhea and intestinal failure

  **Potential cause of diarrhea**                                **Investigations**                                                                                   **Results**
  -------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  Excess bile acid production with deficient retention           SeHCAT scintigraphy                                                                                  0 retention, indicating an excess loss of bile acids
  Active Crohn's disease                                         Small bowel imaging; colonoscopy; fecal calprotectin                                                 Normal MRI of small bowel and capsule endoscopy; normal colonoscopy with biopsies; fecal calprotectin \< 30 mg/kg
  Small bowel disease (celiac disease, autoimmune enteropathy)   Duodenal and jejunal biopsies; plasma tissue transglutaminase antibody                               Normal biopsies; anti-transglutaminase negative
  *Clostridium difficile* infection                              *Clostridium difficile* toxin test                                                                   Positive before fecal transplant; negative repeated tests after fecal transplant
  Pathogenic intestinal infection                                *Salmonella, Shigella, Campylobacter*, and *Yersinia* fecal cultures; PCR for intestinal parasites   Negative
  Systemic infection                                             HIV test; gamma-interferon test for tuberculosis                                                     Negative
  Small intestinal bacterial overgrowth (SIBO)                   Hydrogen breath test                                                                                 Negative
  Use of antidepressant and antiepileptic medications            Observation during drug holiday; therapeutic drug monitoring                                         Treatment dose optimized
  Laxative use                                                   Urine laxative screen repeated with a patient-blinded sampling time                                  Negative × 2
  Neuroendocrine tumor                                           Chromogranin A, gastrin, vasoactive intestinal polypeptide, renin, and aldosterone                   All within the reference range
  Metabolic disease                                              Thyroid function test and synacthen test                                                             All within the normal range

SeHCAT: Selenium homotaurocholic acid test.

###### 

Anti-diarrheal drug treatments, their mechanisms of action, and their treatment results in a patient with severe bile acid diarrhea and intestinal failure

  **Drug**                        **Mechanism of action**                                                              **Treatment effect**
  ------------------------------- ------------------------------------------------------------------------------------ -------------------------------------------------------------
  Colestyramine (Questran^®^)     Bile salt sequestrant                                                                Limited effect
  Colesevelam (Cholestagel^®^)    Bile salt sequestrant                                                                Limited effect
  Pantoprazole                    Proton pump inhibitor                                                                No effect
  Loperamide (Imodium^®^)         Decreases intestinal motility                                                        No effect
  Codeine phosphate               Decreases intestinal motility                                                        No effect; sedation
  Spironolactone                  Increases renal potassium reabsorption                                               No effect on potassium deficiency
  Octreotide                      Antisecretory                                                                        No effect; abdominal pain
  Liraglutide (Victoza^®^)        Increases glucagon-like peptide 1 (GLP-1)                                            No effect; weight loss of 2 kg to 52 kg
  Obeticholic acid (Ocaliva^®^)   Stimulates ileal FGF19 production, thereby inhibiting hepatic bile acid production   Marked reduction of stool volume and fecal electrolyte loss

FGF19: Fibroblast growth factor 19.

Due to having persistent dehydration with a passage of up to 5 L of watery stools per day, the patient was considered for long-term intravenous support. The patient's potassium levels normalized upon infusions of up to 100 mmol of potassium per day, but the urinary sodium became measurable in the 24-h urine samples only after hypertonic NaCl was applied at 2000 mL of 3% NaCl per day. Because intravenous supplementation was necessary to sustain a normal hydration and electrolyte status, the patient was classified as having type III intestinal failure, subtype A3\[[@B20]\]. A scheduled regimen was established with twice weekly infusions of fluids and electrolytes, but the patient remained underweight, had watery diarrhea, and had a poor quality of life.

A trial of obeticholic acid was considered because of the promising initial reports\[[@B14]\]. Following collaboration with Intercept Pharmaceuticals and approval from the National Health Authorities, we were able to start obeticholic acid during admission. In the initial investigation, a repeat *Clostridium difficile* test was positive, and a fecal transplant using an anonymous donor was performed following a short vancomycin taper. Subsequently, the mean number of bowel passages per 24 h decreased from a mean of 17 to a mean of 13. Obeticholic acid was then started at 10 mg per day and increased to 25 mg per day after 4 d. Importantly, obeticholic acid further reduced the number of bowel movements from a mean of 13 to a mean of 7 per 24 h (Figure [1](#F1){ref-type="fig"}). When the number of bowel movements during the two weeks of treatment with 25 mg of obeticholic acid per day was compared with that of the two weeks before treatment, the difference was highly statistically significant (*P* = 0.00001, Mann-Whitney *U* test). While nightly bowel movements had been a persistent problem before the initiation of treatment, these were reduced from a mean of 3 nightly bowel openings to a mean of 2 nightly bowel openings following treatment, and on occasional nights, the patient did not open her bowel during the night. The patient's weight increased by 2 kg to 54 kg, and she was weaned off intravenous fluid support. She resumed social activities, including running, although this occasionally induced an increase in the number of bowel movements (Figure [1](#F1){ref-type="fig"}). She remained sensitive to non-steroid anti-inflammatory drug treatment because a single dose of 400 mg of ibuprofen transiently induced liquid stools (Figure [1](#F1){ref-type="fig"}). The quality of life was estimated using the Euroqol EQ-5D-3L questionnaire (https://euroqol.org). Before the treatment, the patient reported an overall wellbeing of 35 on a 0-100 scale. This increased to 85 following two weeks of obeticholic acid treatment and remained at this level for six months of follow-up.

![Bowel movement frequencies before and during the initial two months of treatment with 25 mg obeticholic acid once daily for severe bile acid diarrhea with intestinal failure.](WJG-24-2320-g001){#F1}

To examine whether the effects were specific to obeticholic acid and whether the effect would last without continued treatment, the patient agreed to a treatment pause. Following three days without obeticholic acid, the patient's condition deteriorated, with an increase in the number of bowel movements in 24 h from 7 to 16 and profound hypokalemia. Shortly after restarting obeticholic acid, the patient's bowel control was reestablished. During 6 mo of follow-up, we observed no adverse effects, and control of Crohn's disease, epilepsy, and depression did not change. A single episode of increased serum pancreatic amylase (266 U/L; reference range: 10-65 U/L) necessitated a pause of the 6-mercaptopurine treatment. Ultrasound examination revealed a normal pancreas and bile ducts, and the p-amylase level normalized. A diagnosis of acute pancreatitis could therefore not be confirmed, and treatment was restarted without further episodes or an increase in the pancreatic or liver function tests. The plasma lipids were slightly elevated before the treatment and decreased during the obeticholic acid treatment. Thus, the patient's total cholesterol decreased from 7.5 to 5.9 mmol/L, and her LDL-cholesterol level decreased from 4.5 to 3.1 mmol/L, while her HDL-cholesterol increased slightly from 2.0 to 2.1 mmol/L. Measurements of fasting serum FGF19 were performed once before and six times during treatment with obeticholic acid, using the Human FGF-19 Quantikine ELISA kit DF 1900 (R&D Systems, Minneapolis, MN, United States). Although the mean FGF19 level increased from 35.7 to 167.0 pg/mL during treatment with 25 mg per day, we observed a marked fluctuation in the serum FGF levels during obeticholic treatment, with serum FGF19 concentrations ranging from 21 pg/mL to 728 mg/mL.

DISCUSSION
==========

This case report demonstrates the challenges related to the diagnosis and treatment of patients with multifactorial chronic diarrhea. In this patient, a thorough and systematic evaluation of several differential diagnoses was pivotal for understanding the causes of chronic diarrhea in the presence of a severely disrupted electrolyte balance and intestinal failure. Because the SeHCAT retention rate was 0 on day 7, an overproduction of bile acids in combination with severe bile acid malabsorption was indicated. In the absence of other causes of chronic diarrhea, we concluded that the patient had severe BAD. Before treatment with obeticholic acid, the patient had intestinal failure with a dependency on intravenous fluid and electrolyte support. To the best of our knowledge, this is the first report of BAD of such severity.

For patients with chronic diarrhea, the SeHCAT scintigraphy identifies those with BAD and, hence, a treatable cause of diarrhea\[[@B8],[@B19],[@B21]-[@B23]\]. It further helps to tailor the treatment. This investigation therefore remains an important tool in the diagnostic workup and should be considered in patients with Crohn's disease and unresolved diarrhea\[[@B6]\].

While this patient was refractory to conventional therapies for diarrhea, she improved both clinically and biochemically following treatment with obeticholic acid. This adds to the promising data that indicate obeticholic acid may improve BAD *via* a modulation of negative feedback signaling of FGF19 on hepatic bile acid production\[[@B14]\]. Obeticholic acid is marketed for the treatment of primary biliary cholangitis and has been investigated in dosages of 10 mg to 50 mg daily for 3 mo\[[@B15]\] and up to 10 mg daily for 12 mo\[[@B16]\]. Pruritus was the most common side effect and occurred in up to two-thirds of the treated patients, even at low doses. We observed no side effects in this patient. Because the treatment was well-tolerated, and the improvements of fluid balance and quality of life were sustained during the follow-up, we did not change the treatment dose.

We measured fasting serum FGF19 levels both before and during treatment and found that obeticholic acid increased FGF19 levels, but with substantial variation between samples obtained during treatment. The finding supports that hepatic bile production is inhibited by FGF19 signaling following the obeticholic acid-induced stimulation of FXR in ileal enterocytes\[[@B12],[@B24],[@B25]\]. It also emphasizes that the use of FGF19 measurement should be validated. In general, FGF19 levels depend on renal function, age, and systemic inflammation\[[@B26],[@B27]\]. In patients with Crohn's disease, FGF19 levels are generally lower than in control patients, and low levels are associated with ileal resection and with active disease, independently of ileal resection\[[@B13]\].

In conclusion, we found that treatment with oral obeticholic acid (25 mg daily) induced a marked and sustained improvement of bowel function, fluid and electrolyte balance, and quality of life in this patient with severe BAD and intestinal failure. Future clinical trials should investigate the long-term clinical effects of obeticholic acid, including safety measures and serum FGF19 dynamics.

ARTICLE HIGHLIGHTS
==================

Case characteristics
--------------------

A 32-year-old woman with chronic diarrhea that had multiple potential causes including bile acid diarrhea, Crohn's disease, and medications for epilepsy and depression.

Clinical diagnosis
------------------

Bile acid diarrhea (BAD), diagnosed by selenium homotaurocholic acid test scintigraphy with 0 bile acid retention after seven days.

Laboratory diagnosis
--------------------

Persistently low plasma levels of sodium and potassium and undetectable 24-h urine sodium excretion, indicating intestinal failure with dependency of intravenous fluid support.

Pathological diagnosis
----------------------

Normal duodenal, jejunal, ileal, and colonic biopsies, indicating quiescent Crohn's disease. Positive *Clostridium difficile* toxin PCR test indicating *Clostridium difficile* colitis.

Treatment
---------

*Clostridium difficile* colitis was treated with vancomycin followed by fecal microbiota transplantation. Bile acid diarrhea was refractory to conventional treatments including colestyramine and colesevelam, and oral obeticholic acid treatment was commenced at 10 mg per day, increasing to 25 mg per day. Upon this, the patient's bowel habits and quality of life improved.

Related reports
---------------

Obeticholic is licensed for primary biliary cholangitis and has been used in non-alcoholic steatohepatitis. It was recently reported that obeticholic acid may improve bile acid diarrhea through induction of fibroblast growth factor 19 that inhibits hepatic bile production.

Term explanation
----------------

BAD--bile acid diarrhea, resulting from excess hepatic production and/or deficient ileal reabsorption of bile acids, which in turn induces colonic fluid and electrolyte secretion and leads to chronic secretory diarrhea.

Experiences and lessons
-----------------------

In patients with chronic diarrhea, a thorough and systematic diagnostic workup may help to differentiate between potential causes of diarrhea. Some patients with bile acid diarrhea are refractory to conventional treatments. Obeticholic acid may be of clinical benefit in these patients.
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